Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Mattel Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.27 (market cap $29.60B), while Mattel Inc trades at $15.03 (market cap $4.30B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.9× Mattel Inc's market cap, and Mattel Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MAT | |
|---|---|---|
Market Cap | $29.60B | $4.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $22.16 |
52-Week Low | $205.48 | $13.05 |
Enterprise Value | $27.56B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Mattel (MAT) trades at $14.74, down 0.34% today, with a bullish technical signal from moving averages and oversold RSI levels. Recent Q2 2026 earnings missed estimates despite 10% revenue growth, reflecting margin pressure from higher costs. The company maintains solid profitability with a 7.78% net margin and attractive valuation at a P/E of 11.22. Cash flow turned negative in 2025 due to increased financing outflows, though operations remain cash-generative.
Outlook is mixed: analyst consensus leans buy (53%) with a $14 price target, but rising expenses and toy market volatility pose risks. The stock's appeal hinges on execution of its entertainment-driven growth strategy and cost management amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
